These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 11816266)

  • 41. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study.
    Hallal A; Cohn SM; Namias N; Habib F; Baracco G; Manning RJ; Crookes B; Schulman CI
    Surg Infect (Larchmt); 2007 Feb; 8(1):73-82. PubMed ID: 17381399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
    Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Borraz C; Gudiol F
    J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Intrathecal use of amikacin and colistin].
    Hachimi A; Charra B; Benslama A; Motaouakkil S
    Ann Fr Anesth Reanim; 2008 Jan; 27(1):113-4. PubMed ID: 18077128
    [No Abstract]   [Full Text] [Related]  

  • 44. Intrathecal administration of amikacin for treatment of meningitis secondary to cephalosporin-resistant Escherichia coli.
    Preston SL; Briceland LL
    Ann Pharmacother; 1993; 27(7-8):870-3. PubMed ID: 8364266
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adult Acinetobacter meningitis and its comparison with non-Acinetobacter gram-negative bacterial meningitis.
    Chen SF; Chang WN; Lu CH; Chuang YC; Tsai HH; Tsai NW; Chang HW; Lee PY; Chien CC; Huang CR
    Acta Neurol Taiwan; 2005 Sep; 14(3):131-7. PubMed ID: 16252615
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin.
    Gleeson T; Petersen K; Mascola J
    J Antimicrob Chemother; 2005 Sep; 56(3):602-3. PubMed ID: 16046467
    [No Abstract]   [Full Text] [Related]  

  • 48. Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intrathecal and intravenous colistin.
    De Pascale G; Pompucci A; Maviglia R; Spanu T; Bello G; Mangiola A; Scoppettuolo G
    Minerva Anestesiol; 2010 Nov; 76(11):957-60. PubMed ID: 20445494
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acinetobacter, an infrequent cause of community acquired bacterial meningitis.
    Reindersma P; Nohlmans L; Korten JJ
    Clin Neurol Neurosurg; 1993 Mar; 95(1):71-3. PubMed ID: 8453820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic vancomycin monitoring in children with hydrocephalus during treatment of shunt infections.
    Bafeltowska JJ; Buszman E; Mandat KM; Hawranek JK
    Surg Neurol; 2004 Aug; 62(2):142-50; discussion 150. PubMed ID: 15261509
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic studies on tobramycin in horses.
    Hubenov H; Bakalov D; Krastev S; Yanev S; Haritova A; Lashev L
    J Vet Pharmacol Ther; 2007 Aug; 30(4):353-7. PubMed ID: 17610409
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.
    Prescott WA; Nagel JL
    Pharmacotherapy; 2010 Jan; 30(1):95-108. PubMed ID: 20030477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period.
    Conen A; Walti LN; Merlo A; Fluckiger U; Battegay M; Trampuz A
    Clin Infect Dis; 2008 Jul; 47(1):73-82. PubMed ID: 18484878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
    Krajewski J; Bode-Böger SM; Tröger U; Martens-Lobenhoffer J; Mulrooney T; Mittelstädt H; Russlies M; Kirchner R; Knobloch JK
    Int J Antimicrob Agents; 2014 Oct; 44(4):363-6. PubMed ID: 25182711
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monitoring of Tobramycin Exposure: What is the Best Estimation Method and Sampling Time for Clinical Practice?
    Gao Y; Hennig S; Barras M
    Clin Pharmacokinet; 2019 Mar; 58(3):389-399. PubMed ID: 30140975
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
    Madsen V; Lind A; Rasmussen M; Coulthard K
    J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel International Clone variants.
    Bahador A; Taheri M; Pourakbari B; Hashemizadeh Z; Rostami H; Mansoori N; Raoofian R
    Microb Drug Resist; 2013 Oct; 19(5):397-406. PubMed ID: 23768166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determination of tobramycin pharmacokinetics in burn patients to evaluate the potential utility of once-daily dosing in this population.
    Vella D; Walker SA; Walker SE; Daneman N; Simor A
    J Burn Care Res; 2014; 35(4):e240-9. PubMed ID: 24043237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of Post-operative Meningitis: Comparison of Meningitis Caused by Acinetobacter spp. and Other Possible Causes.
    Senturk GC; Ozay R; Kul G; Altay FA; Kuzi S; Gurbuz Y; Tutuncu E; Eser T
    Turk Neurosurg; 2019; 29(6):804-810. PubMed ID: 31192440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.